A pre-clinical stage biotech company committed to revolutionizing the treatment landscape of chronic and acute pain. We are focused on delivering safe, effective, and easy-to-use alternatives for the treatment of acute and chronic pain. At Chiima Therapeutics, we are committed to improving the lives of patients with acute and chronic pain conditions by developing and providing access to innovative therapies. Our approach is aimed at preventing pain complications and having patients return to normalcy. Patients suffer from pain in many ways. Pain robs patients of their lives.  Our primary area of focus is endometriosis-related pain and chronic neuropathy. Chiima Therapeutics is currently investigating its lead compound CHM-001 for non-hormonal treatment for moderate to severe endometriosis-related pain in adult women. Our other lead compound is being investigated for the treatment of chronic neuropathy. Our pre-clinical data in both molecules have demonstrated positive Proof of Concept and efficacy data. Both compounds have begun IND- enabling studies. The novel compounds provide an increased level of efficacy that can improve a patient’s quality of life. Patients are sometimes unable to do many of the things they once did without pain. Inadequately managed pain can lead to adverse physical and psychological patient outcomes for individual patients and their families.

​

​

​

​

​